
Early Safety Data Show Tolerability of Apalutamide Plus Carotuximab in Metastatic CRPC
The combination of carotuximab (ENV-105) and standard-of-care apalutamide (Erleada) has been shown to be well tolerated in the first 10 patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in an ongoing phase 2 trial (NCT05534646 …